News
Zynteglo halt re-ignites viral vector safety concerns; analy...
Bluebird Bio’s decision to hit pause on the launch of Zynteglo for beta thalassaemia after two cases of cancer were seen in a clinical trial could see fears over the safety of viral vectors
